Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies.

Campbell, R Keith

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. [electronic resource] - The Journal of family practice Sep 2010 - S20-7 p. digital

Publication Type: Case Reports; Journal Article

1533-7294


Adamantane--analogs & derivatives
Aged
Blood Glucose--drug effects
Diabetes Mellitus, Type 2--drug therapy
Dipeptides--therapeutic use
Dipeptidyl-Peptidase IV Inhibitors--adverse effects
Exenatide
Female
Glucagon--metabolism
Glucagon-Like Peptide 1--agonists
Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin--metabolism
Humans
Hypoglycemia
Hypoglycemic Agents--adverse effects
Incretins--adverse effects
Insulin--metabolism
Liraglutide
Male
Metformin--adverse effects
Middle Aged
Peptides--therapeutic use
Pyrazines--therapeutic use
Receptors, Glucagon
Risk
Sitagliptin Phosphate
Triazoles--therapeutic use
Venoms--therapeutic use
Weight Loss